Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU

The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

Ekta Bagri headshot

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.

Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study

Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.

Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More

The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.

Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders

Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q1 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.

Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News

The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Kevin Cook headshot

Alzheimer's Disease: 5 Stocks on Biotech Radars

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Biogen Inc. (BIIB) Surpasses Q1 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More

The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.